Gan & Lee Pharmaceuticals (603087.SH): GLR2037 tablet Phase I clinical trial completed first subject dosing.

15:39 03/04/2026

Ganli Pharmaceutical (603087.SH) announced that the company's independently developed GLR2037 tablet is undergoing Phase I clinical trials in China, and recently successfully completed the first subject dosing. GLR2037 tablet is a type 1 chemical new drug developed independently by Ganli Pharmaceutical, which is a androgen receptor-protein degrading targeted hybrid (ARPROTAC). The indication for this clinical trial is advanced prostate cancer.

Gan & Lee Pharmaceuticals (603087.SH) announced that the company's self-developed GLR2037 tablet is undergoing a Phase I clinical trial in China, and has successfully completed dosing for the first subject recently. GLR2037 is a novel class 1 chemical drug developed by Gan & Lee Pharmaceuticals, which targets the androgen receptor-protein degradation chimera (ARPROTAC). The indication for this clinical trial is late-stage prostate cancer.

Two big events on the eve of SpaceX's listing: Starship test flight postponed, IPO bundled with Grok AI sparking discussions.

Boji Medical Technology (300404.SZ) subsidiary Danyuan Diabetic Ointment has obtained the approval notice for drug clinical trials.

Evening hot topics on A-share market | Nine government departments jointly issued a document with 64 measures to boost consumption!

Two big events on the eve of SpaceX's listing: Starship test flight postponed, IPO bundled with Grok AI sparking discussions.

Boji Medical Technology (300404.SZ) subsidiary Danyuan Diabetic Ointment has obtained the approval notice for drug clinical trials.

Evening hot topics on A-share market | Nine government departments jointly issued a document with 64 measures to boost consumption!